All In Biotech

Drug Trial Radar · NCT00231764

MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients

Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx

Last checked: Nov 20, 2026Latest source record: Apr 24, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,760 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,760

Actual

Start

Nov 2002

Primary completion

May 2006

Study completion Feb 2008

Sponsor

Lead sponsor
Ekberg, Henrik, M.D.Individual
Sponsor type
Individual
Collaborators
Prof. Philip Halloran, Edmonton, Canada (sponsor); Prof. Yves Vanrenterghem, Leuven, Belgium (Steering Committee Member); Prof. Pierre Daloze, Montréal, Canada (Steering Committee Member); Prof. Thomas C. Pearson, Atlanta, USA (Steering Committee Member); Prof. Ulrich Frei, Berlin, Germany (Steering Committee Member); Prof. Flavio Vincenti, San Francisco, USA (Ass. Steering Committee Member); Prof. Josep Grinyo, Barcelona, Spain (Ass. Steering Committee Member); Hoffmann-La Roche
First posted
Oct 4, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the renal function, as expressed by the glomerular filtration rate at 12 months, in renal transplant recipients receiving mycophenolate mofetil, daclizumab, and corticosteroids as mainstay immunosuppression in combination with low-dose cyclosporine, tacrolimus, or sirolimus, and compare it to that of renal transplant recipients receiving standard immunosuppression with mycophenolate mofetil, normal dose cyclosporine and corticosteroids.

Conditions

  • Kidney Transplantation

Interventions

  • daclizumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GFR calculated from the serum creatinine with the Cockcroft-Gault formula at 12 months posttransplantation

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.